Evolus, Inc. (EOLS)
7.14
-0.55
(-7.15%)
USD |
NASDAQ |
Oct 02, 16:00
7.135
0.00 (0.00%)
After-Hours: 20:00
Evolus Net Income (Quarterly) : -8.052M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -8.052M |
| March 31, 2026 | -10.67M |
| December 31, 2025 | 0.13M |
| September 30, 2025 | -15.74M |
| June 30, 2025 | -17.14M |
| March 31, 2025 | -18.89M |
| December 31, 2024 | -6.791M |
| September 30, 2024 | -19.17M |
| June 30, 2024 | -11.35M |
| March 31, 2024 | -13.11M |
| December 31, 2023 | -11.83M |
| September 30, 2023 | -16.92M |
| June 30, 2023 | -18.14M |
| March 31, 2023 | -14.79M |
| December 31, 2022 | -13.16M |
| September 30, 2022 | -20.28M |
| June 30, 2022 | -23.47M |
| March 31, 2022 | -17.50M |
| December 31, 2021 | -18.18M |
| September 30, 2021 | -19.43M |
| Date | Value |
|---|---|
| June 30, 2021 | -15.60M |
| March 31, 2021 | 6.401M |
| December 31, 2020 | -110.69M |
| September 30, 2020 | -11.46M |
| June 30, 2020 | -21.12M |
| March 31, 2020 | -19.74M |
| December 31, 2019 | -14.51M |
| September 30, 2019 | -26.98M |
| June 30, 2019 | -37.57M |
| March 31, 2019 | -10.98M |
| December 31, 2018 | -12.44M |
| September 30, 2018 | -11.83M |
| June 30, 2018 | -16.43M |
| March 31, 2018 | -6.162M |
| December 31, 2017 | 4.448M |
| September 30, 2017 | -2.634M |
| June 30, 2017 | -2.296M |
| March 31, 2017 | -3.998M |
| December 31, 2016 | -3.743M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 23.00M |
| Corcept Therapeutics, Inc. | 42.14M |
| Veru, Inc. | -6.988M |
| Johnson & Johnson | 5.534B |
| Eli Lilly & Co. | 7.095B |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 84.08M |
| Total Expenses (Quarterly) | 92.14M |
| EPS Diluted (Quarterly) | -0.1221 |
| Enterprise Value | 590.97M |
| Gross Profit Margin (Quarterly) | 66.18% |
| Profit Margin (Quarterly) | -9.58% |
| Earnings Yield | -7.38% |
| Normalized Earnings Yield | -7.672 |